Semax
Also known as: Semax peptide, ACTH(4-7)-PGP, MEHFPGP, Met-Glu-His-Phe-Pro-Gly-Pro
3 notable studies · 3 references
TLDR
Semax is a synthetic ACTH-derived heptapeptide studied for neuroprotection, cerebral ischemia, cognition, neurotrophic signaling, and inflammation, with human clinical research—particularly from Russia—but limited modern independent evidence establishing its efficacy outside those research settings.
At a Glance
Classification: Synthetic heptapeptide; ACTH(4-7) analogue; melanocortin-derived neuropeptide; experimental neuroprotective/nootropic peptide
Semax is a synthetic seven-amino-acid peptide: Met-Glu-His-Phe-Pro-Gly-Pro It was engineered from the ACTH(4-7) fragment of adrenocorticotropic hormone, with the tripeptide Pro-Gly-Pro (PGP) added to improve stability. Despite originating from ACTH, Semax was specifically developed to retain neurobiological activity without the classical hormonal effects of full-length ACTH. Research has focused on: • Cerebral ischemia and stroke • Neuroprotection • BDNF and neurotrophic signaling • Learning and memory • Attention • Oxidative stress • Inflammation • Dopaminergic and serotonergic signaling • Gene expression Semax has been used clinically in Russia and neighboring markets, particularly in neurological contexts, but it is not FDA-approved in the United States. The evidence is stronger than internet descriptions such as “experimental nootropic peptide” might imply—but substantially weaker than would be required to call Semax an established stroke treatment in the U.S.
What Is Semax?
Semax was developed from a short fragment of ACTH, a pituitary peptide best known for stimulating adrenal cortisol production. Researchers discovered that some ACTH fragments appeared to produce behavioral and neurological effects independently of classical adrenal stimulation. The ACTH(4-7) sequence: Met-Glu-His-Phe became a focus of this work. Adding: Pro-Gly-Pro produced the more stable heptapeptide: Met-Glu-His-Phe-Pro-Gly-Pro or Semax. The result is a molecule designed primarily around neural rather than endocrine effects.
What Are Researchers Studying?
Cerebral ischemia and stroke
Stroke and cerebral ischemia are among Semax's most important historical research areas. Russian clinical and experimental studies investigated Semax following ischemic stroke, particularly as an adjunct to conventional treatment. Reported outcomes have included changes in neurological recovery and neurotrophic or inflammatory biomarkers. However, much of this clinical literature is relatively small, geographically concentrated, and not replicated through the kind of large multinational Phase 3 programs expected for modern stroke therapeutics. So: Human stroke research exists. But: Semax is not an FDA-approved stroke therapy.
BDNF and neurotrophic signaling
One of Semax's most interesting experimental effects involves brain-derived neurotrophic factor (BDNF). BDNF participates in: • Synaptic plasticity • Neuronal survival • Learning • Memory • Adaptive neural remodeling Animal experiments have reported changes in hippocampal BDNF expression following Semax exposure. Researchers have also reported effects involving other neurotrophin-related genes and signaling pathways. This provides a plausible mechanism for some of Semax's neuroprotective and cognitive findings. It does not establish that Semax simply “raises BDNF in humans.”
Learning and memory
Semax has been studied extensively in animal models involving: • Learning acquisition • Memory consolidation • Attention • Stress-related cognitive impairment • Experimental brain injury Some experiments report improved learning or memory performance. Human cognitive research also exists, but it is much less extensive than the preclinical literature. Claims that Semax is a proven general-purpose cognitive enhancer in healthy adults therefore go beyond the evidence.
Neuroinflammation
Semax research has identified changes in inflammatory gene expression following experimental cerebral ischemia. Researchers have examined pathways involving: • Cytokines • Chemokines • Innate immune signaling • Leukocyte-related pathways • Neuroinflammatory responses This has led to the hypothesis that part of Semax's neuroprotective activity may involve modulation of the inflammatory response to brain injury.
Oxidative stress
Experimental ischemia produces substantial oxidative stress. Animal studies have reported changes in antioxidant systems and oxidative-damage markers following Semax treatment. These effects may interact with its broader neuroprotective biology. Again, this should be presented as a proposed mechanism, not as evidence that Semax clinically “detoxifies the brain.”
Dopamine and serotonin
Semax has been investigated for effects on monoamine systems. Animal experiments suggest that Semax can influence: • Dopamine • Serotonin • Their metabolites • Associated behavioral responses These findings may contribute to reported effects on motivation, attention, stress responses, and cognition. But Semax should not be classified simply as a dopaminergic stimulant. Its pharmacology appears considerably broader.
Gene expression after brain injury
Modern Semax research increasingly focuses on transcription. Experimental cerebral ischemia produces enormous changes in gene expression. Researchers have reported that Semax modifies expression of genes involved in: • Inflammation • Vascular biology • Neurotrophic signaling • Immune responses • Cell survival This suggests that Semax's biological effects may involve coordinated downstream transcriptional responses, rather than a single conventional receptor interaction.
How Does It Work?
Semax does not have one cleanly established receptor mechanism. Proposed mechanisms include: Neurotrophic signaling Semax influences pathways involving BDNF and related neurotrophins. Melanocortin-related biology Its ACTH-derived structure connects Semax to the broader melanocortin peptide family, although it lacks the classical adrenal-stimulating activity of ACTH. Monoamine regulation Animal experiments report changes involving dopamine and serotonin. Gene-expression modulation Semax changes transcription of numerous genes in experimental brain-injury models. Anti-inflammatory effects Semax may modify inflammatory signaling following cerebral ischemia. Antioxidant effects Experimental research suggests modulation of oxidative-stress pathways. The most accurate description is therefore: Semax appears to exert multiple downstream neurobiological effects rather than behaving as a simple single-target receptor agonist.
What Does the Research Show?
Human research
Human Semax research exists. Clinical studies have investigated it in: • Ischemic stroke • Cerebrovascular disease • Neurological recovery • Cognitive disorders • Optic-nerve disease But the evidence has limitations: • Many studies originated in Russia. • Some publications are Russian-language. • Sample sizes are often relatively small. • Modern independent international replication is limited. • Large U.S./European regulatory-quality trials are lacking. Semax therefore sits above purely preclinical compounds but well below established neurological drugs in evidence certainty.
Animal research
Animal evidence is extensive. Models include: • Cerebral ischemia • Hypoxia • Stress • Learning impairment • Memory impairment • Neuroinflammation • Oxidative injury Researchers have examined behavioral outcomes alongside molecular endpoints such as BDNF, cytokines, monoamines, and gene expression.
In-vitro research
Cellular and molecular experiments have examined: • Neurotrophic pathways • Gene transcription • Oxidative-stress responses • Peptide degradation • Enkephalin-degrading enzymes Interestingly, both Semax and Selank inhibit enzymes involved in degradation of endogenous enkephalins in human serum experiments. That is a mechanistic connection between the two peptides, despite their different structures and primary research areas.
Notable Studies
Semax Effects on the Default Mode Network of the Brain
humanResearchers used functional MRI to investigate changes in resting-state brain-network connectivity following Semax administration, providing direct evidence that the peptide can influence measurable human brain-network activity.
Limitations: Neuroimaging changes do not establish improved cognition, treatment efficacy, or meaningful long-term neurological benefit.
View publication →Semax Regulation of the Expression of Immune- and Vascular-Related Genes in Rat Brain Following Focal Ischemia
animalResearchers examined transcriptional responses following experimental cerebral ischemia and reported Semax-associated changes in genes involved in inflammation, immune responses, and vascular biology.
Limitations: Molecular changes in an experimental rat stroke model do not establish improved clinical outcomes in human stroke.
View publication →Semax and BDNF/TrkB Expression in Rat Hippocampus
animalSemax administration was associated with changes in hippocampal BDNF-related signaling, providing one mechanistic explanation for its reported effects on learning, memory, and neuroprotection.
Limitations: Changes in rat hippocampal BDNF cannot establish cognitive enhancement or neuroprotection in healthy humans.
View publication →What We Still Don't Know
• Long-term human safety • Human pharmacokinetics across administration routes • Optimal exposure • Whether stroke findings replicate internationally • Whether it meaningfully improves long-term stroke disability • Whether it improves cognition in healthy adults • Magnitude and duration of any attention effects • Whether BDNF effects demonstrated in animals occur meaningfully in humans • Which molecular mechanism dominates • Clinical importance of gene-expression changes • Comparative efficacy against established neurological treatments • Whether research-market Semax is chemically equivalent to material used in published studies
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the Semax research with you.
Get the Aminodex Semax Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
Supplier Listings
Disclosure: The owner of Aminodex operates the supplier(s) marked below. These listings are promotion for businesses we own, not independent recommendations. Read our disclosures.